L-Ergothioneine Gold Nanoparticles For Medical Applications
Summary
Guangzhou First People's Hospital has filed USPTO patent application US20260108633A1 for L-ergothioneine-gold nanoparticles (EGT-AuNPs) combining gold nanoparticle imaging contrast with L-ergothioneine antioxidant properties. The application covers contrast agents and antioxidants for medical imaging and renal protection, particularly early diagnosis and treatment of acute kidney injury (AKI). CPC classifications include A61K 49/04, A61K 9/5192, A61K 31/4172, and A61P 13/12, indicating pharmaceutical compositions for kidney therapy and diagnostic imaging applications.
“An application for the EGT-AuNPs in preparing contrast agents and/or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and/or treating acute kidney injury (AKI).”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108633A1 for EGT-AuNPs — gold nanoparticles connected to L-ergothioneine via gold-sulfur bonds — for use as contrast agents and antioxidants in medical imaging and renal therapy.
Patent applicants and researchers developing nanoparticle-based contrast agents or renal-protective antioxidants should monitor this application for prior art and freedom-to-operate implications. Healthcare companies in diagnostic imaging or nephrology therapeutics may find competitive landscape relevance.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
L-ERGOTHIONEINE-GOLD NANOPARTICLES AND PREPARATION METHOD AND APPLICATION THEREOF
Application US20260108633A1 Kind: A1 Apr 23, 2026
Assignee
Guangzhou First People's Hospital
Inventors
Bujie DU, Mingze XU, Xingya JIANG
Abstract
An application for the EGT-AuNPs in preparing contrast agents and/or antioxidants is provided, where the EGT-AuNPs include gold nanoparticles (AuNPs), the AuNPs are connected to L-ergothioneine (EGT) by gold-sulfur bonds, and the antioxidants include medicines for preventing and/or treating acute kidney injury (AKI). EGT-AuNPs with antioxidant activity are designed and synthesized through the combination of the higher imaging contrast of gold and the antioxidant natural product EGT, and they are ultra-small AuNPs, which achieve the combination of CT imaging and antioxidant effects, and are suitable for renal imaging, particularly for the early diagnosis and treatment of AKI, realizing the integration of diagnosis and treatment, circumventing the toxicity of contrast agents present in the conventional nanomaterials, lowering the serum creatinine and urea nitrogen levels, and reducing the degree of renal tubular damage.
CPC Classifications
A61K 49/04 A61K 9/5192 A61K 31/4172 A61P 13/12
Filing Date
2025-05-20
Application No.
19212792
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.